SITE SELECTION FOR CLINICAL RESEARCH IN INDIA by Bangera, Sudhakar & Ms, Latha
Vol 8, Issue 1, 2015 ISSN - 0974-2441
SITE SELECTION FOR CLINICAL RESEARCH IN INDIA
SUDHAKAR BANGERA1*, LATHA MS2
1Program Director, Clinical Development Service Agency, Gurgaon, India. 2Professor of Pharmacology, Hyderabad, India.  
Email: bangerasudhakar@hotmail.com
Received: 30 August 2014, Revised and Accepted: 20 September 2014
ABSTRACT
For biopharmaceutical companies, in order to prevent excessive expenditure, completing a clinical trial on time is crucial. Selection of the right 
study site(s), trained investigators and site coordination team are key factors in determining the timely completion of the study. There are few 
criteria (study and sponsor specific) that have to be met by the study sites to allow them to qualify and participate in the study. By adhering to 
these, the value of the sponsor’s time and money can be enhanced. Though site selection in India is similar to that in other countries, there are a few 
cultural differences that the sponsors should be aware of. Based on our experiences, here we provide guidance to address practical issues that may be 
encountered while selecting a site and an investigator in India. Study sites in India have the potential to become world-class study sites, but require 
an infrastructure and proper training. With an available patient pool along with an unmet health need, Indian sites offer an attractive alternative to 
their foreign counterparts.
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INTRODUCTION
Globalization has opened the gates for the foreign companies to invest, 
establish and conduct business in India. This has led major foreign 
biopharmaceutical companies to focus on conducting clinical studies in 
India, as many are facing challenges for a timely completion of the study 
in other countries, due to various reasons such as cost and deficiency 
of eligible subjects.
The Government of India amended the policies and regulatory 
guidelines (Schedule Y) in 2005 in an attempt to meet global standards, 
and to facilitate the efficient conduct of clinical trials (CTs) by global 
pharmaceutical companies. Well trained and qualified medical 
practitioners (by education and practice), a large treatment-naïve 
population, unmet health needs and generation of quality data, 
along with reforms in the regulatory guidelines has turned India into 
attractive destination for the conduct of CTs. In a survey conducted 
by Kearney, a consulting firm, India ranked second to China in a scale 
which used the US market for comparison and was found to be similar 
in many categories, such as, regulatory systems and timelines [1].
Selecting the right site to conduct a clinical study in a particular 
therapeutic area and to meet the regulatory requirements is a major 
task faced by sponsors globally. Proper site selection will not only result 
in timely completion of the study with minimal data errors (thereby 
generating a high-quality data) but will also result in reduced drug 
development costs.
There has been a steady inflow of CTs to India, and simultaneously 
there has been much debate going on outside India about the quality 
of sites and the data obtained. Though site selection in India does not 
differ much from other countries, there are few issues that are crucial 
and relate to site selection. Even if the responsibilities are delegated to 
a contract/clinical research organization (CRO), it is advisable for the 
sponsor to take on the final responsibility of qualifying the site.
CURRENT RESEARCH PRACTICE
Location and patient pool
The majority of CTs are, at present, concentrated in the major cities 
of India i.e. Mumbai, Bengaluru, Chennai, Kolkata (formerly known 
as Bombay, Bengaluru, Madras and Calcutta respectively), Delhi, 
Ahmedabad, Pune and Hyderabad, due to the availability of medical 
centers equipped with an adequate infrastructure. These cities are 
also well connected by road and air, thus aiding easy and better 
transportation. However, there is a gradual shift to the next level of 
cities and bigger towns that take into account the availability of patient 
pools.
Until now, unlike the West, there has been no deficiency of patients 
and the requirement to advertize for patients has been rare, as every 
physician has an adequate patient pool. The number of treatment naïve 
patients for any disease is very large in comparison to Europe or USA.
Identifying an investigator
A qualified investigator to conduct the CT is identified, and the study 
site is selected. In exceptional cases, in well-established institutions, 
the investigator may be identified later. Selection of the investigator is 
usually done via one of the following methods.
1. Database: Most Indian sponsors and CROs have databases of 
investigators. However, a central database of good clinical practice 
(GCP)-trained investigators in India is not available.
2. Previous experience with an investigator is taken into consideration 
and whether the proposed study is in the same therapeutic field. 
However, if the investigator has conducted a previous study properly 
and completed on time, they will have more probability of being 
chosen for the next study in the same therapeutic area. This is one 
of the commonly followed methods in identifying an investigator.
3. Referral: Through contacts and known principal investigators (PIs), 
a referral is often sought. This has been found to be very reliable on 
many occasions
4. Internet: Contact details of medical practitioners in a particular 
therapeutic area and in the required location can be searched for 
via the internet. This will often be the method of last resort as the 
contact details may not have been updated, and there is no means of 
authenticating the information available. One can get the information 
through the clinical trials registry of India (CTRI) wherein, contact 
details of the investigators will be listed for a registered study. 
Based on the therapeutic area, one can identify the investigators. 
Searches can also be made by looking in local journals to find who 
has contributed in different therapeutic areas. Few of the medical 
fraternity (associations) share the contacts of their members on the 
internet.
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Many well trained medical practitioners are located in major cities 
due to the availability of good infrastructure; hence, many trials are 
conducted in these cities. Availability of trained investigators, large 
drug-naïve patient pool, and good connectivity, as well as effective 
transport facilities in smaller (tier 2) cities and towns make them an 
attractive alternative.
There are institutes where pharmacologists and other non-clinicians 
are principal investigators and internal medicine practitioners 
(e.g. neurologists, cardiologists, etc.) as sub-investigator!
Since CTs take time to initiate, it would always be best to keep discussing 
to investigators on fortnightly basis to make sure that they have not 
resigned or are planning to change institutes or even retire.
Site coordination team
Since the investigator’s main focus is on clinical practice and has 
little time for clinical research, it is important that a qualified and 
dedicated site coordination team be in place. This could comprise of a 
sub-investigator, research pharmacist, and a site coordinator.
Infrastructure
The site should have the necessary infrastructure to conduct the 
study, such as clinical and laboratory facilities, specimen storage 
facilities and other study specific requirements to conduct the study. 
Some of the local labs may not have local accreditation to National 
Accreditation Board for Testing and Calibration Laboratories (NABL). 
A list of suspended and withdrawn accreditations can be obtained 
from the NABL website.
Internet facility may not be available for electronic case report form 
entry. A mobile data card can, therefore, be used as an alternative.
Most cities and towns in India have power outages frequently through 
the day and night. A back-up power supply is, therefore, always 
necessary.
Patient pool
Availability of the patient pool is one of the important factors in 
considering a site. If the site is a tertiary referral hospital in the district 
headquarters, or consists of a smaller local population where patients 
visit the site from far off places (due to the availability of physicians, 
infrastructure and all treatment under one roof), the site may not be 
feasible, especially if the study demands frequent visits or prolonged 
follow-up. However, the epidemiology of the disease being studied 
should also be considered. When the study is long, a lot of patients fail 
to return for visits because of the distance that they have to travel to a 
tertiary care center. A site at a tier-2 city would be more appropriate. 
One should also consider if the patient population is from the residents 
or the floating population.
Connectivity
Connectivity by road and air is one of the pre-requisites in selecting a 
site, to save time in travelling when performing frequent monitoring, 
transport of samples to the central laboratory within the specified time, 
patients to commute (time spent) and safety of monitors. Currently, 
as most cities/towns are well connected by road/train, monitors can 
travel to the nearest place by air and then by road for monitoring. Study 
sites in the North-Eastern states are not usually selected due to poor 
connectivity.
Local political issues
At times, there can be long-standing political issues that may call for 
“city shutdown,” which can deviate the visit schedule of the patients and 
Monitors. Hyderabad is one example. There are states, where CTs are 
not allowed (for now) e.g. Madhya Pradesh.
Climate
A few cities in India have hot and humid temperature conditions 
(costal), whereas other cities are just hot (Delhi, Hyderabad, etc.). Room 
temperature can vary 15°C (59°F) in the winter to 45°C (113°F) in the 
summer.
Site feasibility
Study site feasibility must be conducted by the sponsor to evaluate the 
site, before the final selection of the site is made unless the sponsor 
has previously worked with the investigator or site. Availability of 
patients in the required therapeutic area should be confirmed prior 
to site feasibility as the disease under study may not be prevalent in 
a particular geographic area. Other factors such as congenital enzyme 
deficiency syndromes, different standards of care (though India mostly 
follows western textbooks for treatment protocols) and the availability 
of alternative medicine systems such as Ayurveda, Homeopathy, Siddha, 
Unani, indigenous medicines, and non-availability of certain drugs for 
emergency use, should also be verified.
What about the CRO personnel’s experience in working with these 
sites? It is important that CRO personnel should have had experience 
with the site and at least have confidence in working with them.
Site feasibility may be done initially by telephone and later by visiting 
the site. Some sites may not have the required infrastructure; visiting the 
site not only helps to evaluate the existing infrastructure but also in the 
evaluation of the investigator and the study team.
Pre-visit
Site feasibility questionnaire
• A study specific questionnaire should be prepared including the 
details about the investigator (and study team), the investigator’s 
willingness to conduct the study, study specific requirements and 
required infrastructure at the site
• Qualifications and training of the investigator and contact details, 
whether s/he is GCP trained or not, experience in conducting CTs 
in the required/related therapeutic area
• Availability of the study team; if available, training, experience and 
other relevant details regarding the team should be obtained
• Patient pool - Availability of patients in a particular therapeutic area 
under study
• Ethics committee (EC) - The constitution, operating procedures and 
frequency of meetings
• Laboratory and clinical facilities, and other infrastructures: If 
accreditation of the labs is required
• Study specific details such as experience with similar compounds/ the 
study drug, should also be collected
• Information on whether the investigator has received any warning 
letters from any regulatory authority or has been disqualified should 
also be collected in the questionnaire. India does not have a list of 
disqualified investigators on the internet
• Involvement in any other CTs, similar or unrelated to assess how 
much time the investigator can devote to this study
• Role and obligation(s) of site management organization if involved, 
their role also has to be specified.
Establishing a contact
An investigator should be initially contacted via telephone or email 
to determine their willingness to conduct the study. The investigator 
may respond immediately, there may be a delayed response, or 
they may not respond at all. An investigator’s interest or disinterest 
to conduct a study can be identified only if contact is established. 
Establishing initial contact can sometimes be a very difficult task for 
many sponsors.
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If an investigator is willing to conduct a clinical study, then a 
study-specific questionnaire can be sent to the site (via e-mail, facsimile, 
courier or by post), requesting the investigator to return the completed 
questionnaire. Based on the feedback, received from the investigator, 
the site may be considered suitable to conduct the study if it fulfills the 
sponsor requirements.
A protocol (or synopsis) should be sent in advance so that any 
questions or concerns that the investigator may have can be clarified. If 
the investigator has read the protocol before the meeting, it shows the 
investigator’s interest.
Sometimes, due to some obligations, an investigator may agree to 
conduct a study, but subsequently may due to various reasons, such as a 
busy work schedule, or other technical issues be not so keen to conduct 
the study.
Fixing an appointment helps to schedule the meetings at a time suitable 
to both the sponsor and investigator. Investigators should be informed 
to keep the letterhead, stamp, updated curriculum vitae (CV), a copy 
of degree certificate, a copy of the registration with Medical Council of 
India (MCI) handy during the site feasibility visit. Though the majority of 
the investigators value the appointment, it may sometimes be canceled 
due to some unforeseen circumstances. Lack of communication from 
the investigator in such circumstances may result in the loss of valuable 
time for sponsors. Hence, it is advisable to re-confirm the appointment 
1-2 days before attending.
During the site feasibility visit
The pre-study visit (site feasibility visit) must be conducted by the 
sponsor (even if responsibilities/obligations are transferred to a CRO), 
provided the investigator is willing to conduct the study.
During this visit, information obtained in the feasibility questionnaire 
is verified, evaluated and assessed. A site qualification visit by the 
sponsor’s representative is always required to interview and assess 
the personnel, their experience, capability to conduct the CTs, and also 
to estimate the available patient pool at the site. The study protocol is 
discussed, and all concerns should be addressed in this visit. This is 
the proper time to highlight any limitations at the site and to ensure 
compliance with criteria required to participate in the study. Most 
investigators can assess whether they can participate in the proposed 
study during the site qualification visit. A site is selected only if the 
sponsor’s representative is satisfied that it meets the previously 
established protocol-specific requirements.
Sponsors will be concerned about the recruitment of trial subjects at the 
required rate, so that enrollment will be completed within the stipulated 
period. Similarly, investigators too may have few concerns regarding 
a foreign sponsor’s awareness of India’s specific issues and cultural 
differences. This visit will be a platform during which both can discuss, 
express their concerns and can resolve any issues, if any, amicably.
Each new investigator has to be evaluated thoroughly, and an 
assessment can be made done to a certain extent during the initial 
telephonic contact and later in the site feasibility visit.
In this visit the following activities should be carried out:
• Verification of the investigator’s qualifications (education and 
training) to conduct the CT in the required therapeutic field. It should 
not happen that a study on hypertension is been conducted by a 
neurologist. It should also be verified if s/he is eligible to conduct the 
study in India as some foreign medical degrees are not recognized 
by the MCI
• Experience in conducting CTs; number of patients recruited and 
completed in a similar CT should also be ascertained
• Availability of the study team, qualifications and their experience in 
conducting CTs
• Verification of a patient database if any: Most investigators do not 
maintain a patient database and even if they did, they may not be 
willing to share the details. A few investigators may not wish to enroll 
patients from their database, for fear of losing their clinical practice. 
The number of patients that can possibly be recruited at the site for 
the study should also be estimated
• Verification of infrastructure: The site should have study-specific 
infrastructure such as storage facilities, centrifuge, facilities to 
conduct clinical investigations, Internet, communication, imaging 
capabilities, etc. The availability and quality of the infrastructure 
should be verified physically during the site visit. Some sites may 
not have the required study specific infrastructure; which may have 
to be provided by the sponsor
• Institutional EC (IEC): Presence of an IEC should be ascertained. 
If possible, a copy of the EC standard operating procedure, list of 
members should be obtained; EC constitution should also be in 
accordance with the regulatory guidelines (Schedule Y of Drugs 
and Cosmetics Act); one of the specifications is that the chairperson 
should not be from the same institution, in order to prevent bias; 
hence the list of members should be verified. Information regarding 
the EC, such as its accreditation/registration with any national 
regulatory agency, processing fee, frequency of meeting, possibility 
of granting conditional approval pending Drugs Controller General 
India NOC etc. should be obtained
• Any other study specific requirements should be assessed for the 
availability and quality
• During the site visit, the study protocol should be discussed after 
obtaining confidentiality agreement signed, and a copy of the 
protocol synopsis can be given to the investigator. Less awareness 
among some new investigators regarding this agreement requires 
the sponsor to explain the salient features including the legal points 
before the confidentiality agreement is signed
• If found feasible, and the investigator is willing to conduct the 
study, an investigator’s consent letter to conduct the study (such as 
statement of investigator, USFDA form 1572), a signed up-to-date 
copy of their CV may must be obtained; since some of requirement 
such as letterhead, updated CV, copy of degree certificate and MCI 
registration details may not be available, these can be collected later.
Schematic representation of site selection process is depicted in Fig. 1.
Utilization of laboratory services
Feasibility of utilizing the central or institutional laboratory for the 
study specific investigations at the site should be discussed and 
assessed during the site feasibility visit.
When the facilities of a central laboratory are utilized, problems related 
to issues such as collection of samples from site, storage, transport to 
the central laboratory, possibility of repeat tests should be considered 
and coordinated throughout the study. Using the services of a central 
laboratory for laboratory investigations though maintains uniformity, 
but also has practical disadvantages in terms of coordination, 
insufficient samples, repeat tests etc.; utilizing the institutional 
laboratories to perform laboratory investigations can be considered as 
an alternative. However, certain issues such as accreditation, uniformity 
in test methods can be a concern if the site’s laboratory is used, which 
needs to be addressed and resolved.
Drawbacks
Investigator
Updated contact details of the investigator may not be available via the 
internet, thereby posing a difficulty in establishing contact. Sometimes, 
the investigator may not respond to mail/telephone call(s), even 
though they are interested in conducting the trial; this often happens 
due to a variety of reasons, such as busy schedule, resulting in repeated, 
frequent telephone calls until the contact is established. It is advisable 
to find out a convenient time to contact the investigator as sometimes 
it is difficult to contact them, even during the course of the study. The 
reasons they do not respond to an email can vary, from not being 
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well-versed with using a computer, limited technical knowledge and 
reluctance to check e-mails.
A telephone assessment cannot determine if an investigator can 
dedicate the time to conduct a study and cannot provide a clear picture 
of the available patient pool.
Training
Our medical graduates are trained to master the art of clinical practice, 
rather than clinical research during their training period and preparing 
them as treatment providers, rather than clinical research scientists. 
This has resulted in fewer GCP trained investigators capable of 
conducting global trials in India. Investigators depend on their mentors 
and sponsors for guidance while conducting a study.
Inadequate funds and infrastructure, overburdened by work, and 
administrative hurdles, are adding to the problems. Moreover, 
investigators lack adequate knowledge about the regulatory 
requirements of India.
Unlike the US, In India, there is no official government website that 
provides a list of investigators who have received warning letters or 
have been blacklisted by the regulatory authority. However, now Govt 
of India has brought major regulatory changes in the Schedule Y of 
Drugs & Cosmetics Act of 1940 and Rules 1945. Central Drugs Standard 
Control Organization (CDSCO) headed by Drug Controller General of 
India (DCGI), is now planning for accreditation EC, Investigator and 
study sites, of which accreditation of EC is ongoing.
Our observation
Sponsors are concentrating on Hospital/Institutions/Medical Colleges 
to conduct their studies which are limited in numbers and available 
GCP-trained investigators are pre-occupied with other studies; hence 
it is advisable to approach specialist medical practitioners who are 
working independently in clinics, but experience, qualifications and 
availability of the support team should be emphasized. In such cases, an 
independent EC can be utilized for the review of documents. This will 
help to approach the drug-naïve patients, benefitting large population 
and also to minimize the commercialization of the CTs.
Addressing the un-met health needs and beneficence to patients 
are the driving force for investigators to conduct a study. However, 
sometimes, motivating an investigator and the team by regular contact 
via telephone, e-mail and site visits will help enhance the pace of 
recruitment.
Concerns
Investigators in towns and smaller cities without doubt have the required 
patient pools to conduct a CT, but also have to face challenges such as 
maintaining quality, enrollment at the required pace and balancing 
clinical research and patient care. There is also growing concern that 
poor, illiterate patients may be exploited, thus violating GCP principles. 
Due to the low literacy rate and usage of many vernacular languages, 
the informed consent form (ICF) and patient information sheet needs 
to be kept very simple, easily understandable and should be translated 
into the local languages (there are 22 languages recognized by the 
constitution of India [2], depending on the site’s location, the ICF and 
other patient information sheets may have to be translated into at least 
two or three languages, depending on the region).
According to a market report by Varawalla et al. [3], “India has 10,000 
GCP-trained clinical research professionals, and 1500 GCP-trained 
investigative sites” (Varawalla et al. 2011), indicating the limitation of 
selecting experienced investigators in conducting global trials in India.
In smaller cities and towns, availability of GCP-trained study teams will 
be a concern. Hence, site personnel need to be trained accordingly to 
study specific needs in order to achieve error free quality data. 
Government of India is trying to address this issue by training the 
Investigators. Ministry of Science & Technology has set up Clinical 
Development Service Agency, an extramural unit of translational 
Health Science and Technology Institute to cater this need of the hour. 
This agency is a not for profit organization which facilitates training 
Figure 1: Site selection process in India
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of investigators, EC members to ensure they are trained to face the 
challenges of conducting a clinical trial. This organization focus on the 
promotion of the scientific research. They also offer other services such 
as preparation of study documents and other study related activities.
CONCLUSION
Proper site selection is the key factor in determining timely completion 
of the study, without any major hurdles. Hence, many activities need 
to be performed and should be done with utmost care. The site has 
to be evaluated continuously throughout the study since it is not a 
one-time activity performed at the time of site selection. As problems 
may be expected to arise at any time during the study, which can 
delay its completion, continuous and vigilant evaluation of the site is 
absolutely necessary. Sponsors have to dedicate a lot of time and effort 
on this aspect. With proper training and supervision, many sites and 
institutions in towns and districts can be utilized.
A well-defined site selection and site management procedure is 
required to protect a company’s expenditure; successful completion of 
a study within a budget and timelines and to ensure high performance 
and competitiveness (not just getting high numbers of patients who do 
not comply with the protocol specified visits or high screen failures), 
meeting global and Indian regulations and guidelines generating high 
quality data. With adequate training, study sites in India can attain 
world class status.
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